Chitosan nanoparticles containing fusion protein (Hspx–PPE44–EsxV) and resiquimod adjuvant (HPERC) as a novel booster vaccine for Mycobacterium tuberculosis
Restricted accessResearch articleFirst published online July, 2022
Chitosan nanoparticles containing fusion protein (Hspx–PPE44–EsxV) and resiquimod adjuvant (HPERC) as a novel booster vaccine for Mycobacterium tuberculosis
This study attempted to explore the immunogenicity of chitosan nanoparticles containing fusion protein (Hspx–PPE44–EsxV; HPE) and resiquimod adjuvant (HPERC) in BALB/c mice. HPE was initially expressed in E. coli BL21 cells. HPE and resiquimod adjuvant were then encapsulated in chitosan nanoparticles (HPERC). One group of mice were subcutaneously vaccinated on days 0, 14, and 28 with HPERC, and the other group was primed with bacilli Calmette-Guérin (BCG) on day 0 and then boosted with HPERC on days 14 and 28. Two weeks after the last injection, IFN-γ, IL-4, and IL-17 in spleen cell culture supernatants, and IgG2a and IgG1 titers in sera were measured. HPERC size was 130.84 ± 12.08 nm (n = 5). Zeta potential of HPERC was 29 ± 4 mv. The highest IFN-γ concentration was detected in BCG-primed mice that were boosted with HPERC. In addition, IL-17 production was significantly increased in all groups compared with that of control, except in those that received nanoparticle (NP), adjuvant (ADJ), NP/ADJ, and fusion protein (Hspx–PPE44–EsxV) (HPE). Comparison of IFN-γ and IL-4 concentration determined that Th1 was activated in BCG-primed and HPERC-boosted group in comparison to the other groups. No significant difference in concentration of IL-4 was observed between groups receiving HPERC and BCG-primed and HPERC-boosted group in comparison to group BCG. Concentrations of IgG2a and IgG1 also increased compared to the control group and the rate of IgG2a was higher compared to IgG1. Chitosan containing HPERC vaccine could induce a high level of specific cytokines in mice. The group of mice which first received BCG and then HPERC as booster vaccine could produce significant amounts of IFN-γ, IL-17, and IgG2a.
BanulsA-LSanouAVan AnhNT, et al.Mycobacterium tuberculosis: ecology and evolution of a human bacterium. J Medical Microbiology2015; 64(11): 1261–1269.
2.
ComasICoscollaMLuoT, et al.Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genetics2013; 45(10): 1176–1182.
3.
GongWLiangYWuX. The current status, challenges, and future developments of new tuberculosis vaccines. Hum Vaccines Immunotherapeutics2018; 14(7): 1697–1716.
4.
FrancoARPeriF. Developing new anti-tuberculosis vaccines: focus on adjuvants. Cells2021; 10(1): 78.
5.
WHO. Global Tuberculosis Report 2020. Geneva: World Health Organization
6.
MauryaSKAqdasMDasDK, et al.A multiple T cell epitope comprising DNA vaccine boosts the protective efficacy of Bacillus Calmette–Guérin (BCG) against Mycobacterium tuberculosis. BMC Infectious Diseases2020; 20(1): 1–14.
7.
RoyPVekemansJClarkA, et al.Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study. The Lancet Glob Health2019; 7(12): e1655–e63.
8.
Vasconcelos-JuniorACde Araújo-FilhoJAda SilvaEB, et al.Limitations of the BCG vaccine and new prophylaxis strategies against human tuberculosis. Einstein2009; 7: 383–389.
9.
LyadovaIPanteleevA. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediators Inflammation2015; 2015: 1–13.
10.
KimWSKimJ-SChaSB, et al.Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strain. Oncotarget2016; 7(18): 24962.
11.
KwonKWKimWSKimH, et al.Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K. Scientific Reports2017; 7(1): 1–13.
12.
XinQNiuHLiZ, et al.Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice. PloS One2013; 8(8): e72745.
13.
AhsanMJ. Recent advances in the development of vaccines for tuberculosis. Ther Advances Vaccines2015; 3(3): 66–75.
14.
KhoshnoodSHeidaryMHaeiliM, et al.Novel vaccine candidates against Mycobacterium tuberculosis. Int Journal Biological Macromolecules2018; 120: 180–188.
15.
UsmanMMIsmailSTeohTC. Vaccine research and development: tuberculosis as a global health threat. Central-European Journal Immunology2017; 42(2): 196.
16.
MustafaAS. In silico analysis and experimental validation of Mycobacterium tuberculosis-specific proteins and peptides of Mycobacterium tuberculosis for immunological diagnosis and vaccine development. Med Principles Pract2013; 22(Suppl. 1): 43–51.
17.
AndersenP. TB vaccines: progress and problems. Trends Immunology2001; 22(3): 160–168.
Junqueira-KipnisAPMarques NetoLMKipnisA. Role of fused Mycobacterium tuberculosis immunogens and adjuvants in modern tuberculosis vaccines. Front Immunology2014; 5: 188.
20.
GavinALHoebeKDuongB, et al.Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science2006; 314(5807): 1936–1938.
21.
AlvingCRPeachmanKKRaoM, et al.Adjuvants for human vaccines. Curr Opinion Immunology2012; 24(3): 310–315.
LiWLiMDengG, et al.Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice. Mol Medicine Reports2015; 12(2): 3073–3080.
24.
MarongiuLDoniniMToffaliL, et al.ESAT-6 and HspX improve the effectiveness of BCG to induce human dendritic cells-dependent Th1 and NK cells activation. PloS One2013; 8(10): e75684.
25.
KnudsenNPHNørskov-LauritsenSDolganovGM, et al.Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics. Proc Natl Acad Sci2014; 111(3): 1096–1101.
26.
HanifSAl‐AttiyahRMustafaA. Molecular cloning, expression, purification and immunological characterization of three low‐molecular weight proteins encoded by genes in genomic regions of difference of Mycobacterium tuberculosis. Scand Journal Immunology2010; 71(5): 353–361.
27.
RomanoMRindiLKorfH, et al.Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). Vaccine2008; 26(48): 6053–6063.
28.
MoradiBSankianMAminiY, et al.A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses. Iranian Journal of Basic Medical Sciences2020; 23(7): 909.
29.
AminiYTafaghodiMJamehdarSA, et al.Heterologous expression, purification, and characterization of the HspX, Ppe44, and EsxV proteins of Mycobacterium tuberculosis. Rep Biochemistry Molecular Biology2018; 6(2): 125.
30.
KamatVBodasDPaknikarK. Chitosan nanoparticles synthesis caught in action using microdroplet reactions. Scientific Reports2016; 6(1): 1–4.
31.
DolanK. Laboratory animal law: legal control of the use of animals in research. John Wiley & Sons, 2008.
32.
MansuryDGhazviniKAmel JamehdarS, et al.Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV. Artificial cells, Nanomedicine, Biotechnology2019; 47(1): 370–377.
33.
TangJYamW-CChenZ. Mycobacterium tuberculosis infection and vaccine development. Tuberculosis2016; 98: 30–41.
34.
YokoyamaMZhangJWhittonJL. DNA immunization: effects of vehicle and route of administration on the induction of protective antiviral immunity. FEMS Immunol Med Microbiol1996; 14(4): 221–230.
35.
RodriguesLCPereiraSMCunhaSS, et al.Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. The Lancet2005; 366(9493): 1290–1295.
36.
DantasOde A XimenesRde FPM de AlbuquerqueM, et al.A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil. The International Journal Tuberculosis Lung Disease2006; 10(5): 536–541.
37.
BasarabaRJIzzoAABrandtL, et al.Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine2006; 24(3): 280–286.
38.
BuddleBWedlockDParlaneN, et al.Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infect Immunity2003; 71(11): 6411–6419.
39.
ŞenelSKremerMKaşS, et al.Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials2000; 21(20): 2067–2071.
40.
HemmatiFSalehiRGhotaslouR, et al.The assessment of antibiofilm activity of chitosan-zinc oxide-gentamicin nanocomposite on Pseudomonas aeruginosa and Staphylococcus aureus. Int J Biol Macromolecules2020; 163: 2248–2258.
41.
GhendonYMarkushinSKrivtsovG, et al.Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virology2008; 153(5): 831–837.
42.
DockrellDHKinghornGR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother2001; 48(6): 751–755.
43.
ChangBACrossJLNajarHM, et al.Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine2009; 27(42): 5791–5799.
44.
IgartuaMPedrazJL. Topical resiquimod: a promising adjuvant for vaccine development?Expert Review Vaccines2010; 9(1): 23–27.
45.
LiQYuHZhangY, et al.Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Scand Journal Immunology2011; 73(6): 568–576.
46.
NiuHHuLLiQ, et al.Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10. 4–Hspx Vaccin2011; 29(51): 9451–9458.
